

Figure S1, related to Figure 1
S1A. E0771 tumor volume over time corresponding to Fig.1P. Individual growth curve are shown in dotted lines whereas the average (same as in Fig.1P) is shown in plain.
S1B. Py230 tumor volume over time corresponding to Fig.1R. Individual growth curve are shown in dotted lines whereas the average (same as in Fig.1R) is shown in plain.



Figure S2, related to Figure 2
S2A. E0771 tumor volume over time corresponding to Fig.1H.
S2B. Individual growth curve shown in dotted lines whereas the average (identical to S2A) is shown in solid.
Statistics:
S2A. Two-way Repeated measures ANOVA with Tukey's multiple comparisons post hoc test. Individual data points are represented together with mean and sem.
For all, * $p<0.05$, ** $p<0.01$, *** $p<0.001$.
Significances are shown as:
* for WT-LFD vs WT-WD,
# for WT-LFD vs ApoE-WD,
& for WT-LFD vs LDLR-WD,
$ for WT-WD vs ApoE-WD.



Figure S3, related to Figure 3
S3A-C. Plasma insulin (S3A), blood glucose (S3B), and (S3C) plasma NEFA upon terminal collection.
S3D. Py230 average tumor volume over time corresponding to Fig.3M.
S3E. Individual growth curves shown in dotted lines whereas the average (identical to S3D) is shown in solid.
S3F. E0771 tumor volume over time corresponding to Fig.3H.
S3G. Individual growth curves shown in dotted lines whereas the average (identical to S3F) is shown in solid.
Statistics:
S3A-C. Unpaired t test.
S3F. Two-way repeated measures ANOVA with Tukey's multiple comparisons post hoc test.
Individual data points are represented together with mean and sem.
For all, * $p<0.05$, ** $p<0.01$, *** $p<0.001$.
Significances are shown as:
* for WT-LFD vs WT-HFD,
# for WT-LFD vs ApoE KO-HFD,
$ for WT-HFD vs APOE KO-HFD.



Figure S4, related to Figure 4.

S4A. E0771 tumor volume over time corresponding to Fig.4I. Individual growth curve shown in dotted lines whereas the average (identical to Fig. 4I) is shown in solid.

S4B. Total 3H radioactive counts in tumors 16 h post 3H-triolein bolus.

S4C, D. Fluorescence intensity in E0771 cells treated with (C) 100nM of C16-Bodipy and (D) 5µg of LDL-pHrodo™ Red.

S4E-F. Normalized fluorescence intensity in E0771 cells treated with 100nM of C16-Bodipy or 2µg of LDL-pHrodo™ Red in the presence of (E) Cd36 inhibitor sms121 or (F) Rac inhibitor EHT 1864 at the indicated dose. Experiments were repeated 2-3 times each independently.

S4G. Body weight of WT females fed a 90% fat KD (pink circles, n=6) or a low fat KD-Ctrl (brown triangles, n=5) before E0771 injections. 8-week-old mice were placed on diets for 4 weeks before E0771 cells injection and maintained on their diet during the 3 weeks of breast tumors growth. KD-ctrl: low fat diet, 10% kcal from fat and 10% kcal from proteins. KD: ketogenic diet, 90% kcal from fat.

S4H. Fat mass as the percentage of total body weight after 4 weeks on diets.

S4I-K. Blood glucose (I), plasma (J) triglycerides, and (K) NEFA in the randomly fed state prior to E0771 injections.

S4L. Tumor growth of E0771 cells in KD and KD-ctrl fed mice. Individual growth curve shown in dotted lines whereas the average is shown in solid.

Statistics:

S4A,L. Two-way repeated measures ANOVA with Sidak's multiple comparisons post hoc test. Significance is shown as * for LFD vs KD (S4A) and * for KD-ctrl vs KD (S4L) .

S4B,G-K. Unpaired t test.



Figure S5, related to Figure 5
S5A. Fat mass as percentage of total body weight one day prior to collection (experimental day 124).
S5B-D. Plasma levels of (B) NEFA, (C) glucose and (D) insulin at euthanasia (experimental day 125).
S5E. E0771 tumor volume over time corresponding to Fig.5H-I. S3F. Individual growth curves are shown.
Statistics:
S5A-D. Two-way ANOVA with Tukey's multiple comparisons post hoc test.
Individual data points are represented together with mean and sem.
For all, * p<0.05, ** p<0.01, *** p<0.001.